Equity
€952,385 ▲ 10.9%
JOLYPHARMA has made a profit without a break since 2021.
JOLYPHARMA
Lifetime
20 annual accounts with figures on one time axispeak €186,564 (2024)
€169,801▼ 9.0%
lowest -€26,291 (2017)
€93,466▼ 10.9%
peak €952,385 (2025)
€952,385▲ 10.9%
€249,329▼ 15.0%
peak 1.1 FTE (2006)
-not published
Board3 names since 2018
-
Documentsfilings and deeds
12-08-202612 days late
2025abbreviated format
Debts from €293,454 to €249,329
Key points
from the 2025 annual accountsFilings
20 annual accounts since 2006
Eight of the last ten came late. The 2020 accounts came latest: 87 days after the end of the period.
Position in the sector
79.3%
Higher solvency than 89% of companies in retail trade. Sector median 36.9% · 13,246 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 20,135 companies had the same profile as JOLYPHARMA has now. Each dot stands for 51 companies, two years later.
95.0%
were still trading
4.7%
stopped another way
0.2%
went bankrupt
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 20,135 companies, not a prediction for JOLYPHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0473899537
New director
appointed, resigned · Director discharge: · Gazette deed
Resignation: (director)
Director discharge: · Gazette deed
Reappointments: (managing director) and (director)
Board meeting of 20-07-2018 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| JOLYPHARMA Riemst | €1.2m | €169,801 | 79.3% | - |
| PHARMACIE SCHOUTETEN Comines-Warneton | €1.2m | €171,634 | 55.3% | 0.8 |
| APOTHEEK TINE MARTENS Hechtel-Eksel | €1.2m | €199,864 | 14.4% | 0.9 |
| APOTHEEK BORMANS BOVELINGEN Heers | €1.3m | €207,810 | 6.1% | 0.2 |
| Apotheek DELNAT Tongeren-Borgloon | €1.0m | €210,617 | 40.6% | 0.7 |
| FARMA SPRUYT Kortenberg | €1.2m | €179,667 | 84.2% | - |
| Apotheek Janssens-Vancluysen Leuven | €1.2m | €155,486 | 47.6% | - |
These companies have the same main activity as JOLYPHARMA: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €1m and €1.3m, founded between 1997 and 2004.
Official details
Source: KBO- Status
- Active since 24-01-2001Normal situation
- Activity
- Retail sale of pharmaceutical productsNACE 47730
- Establishment unit
- 2.165.543.4103770 Riemst, since 08-10-2007
- Financial year end
- 31 December
- Peppol
- Reachable since 18-11-2025
Annual accounts 2025
- ≈ €800,000estimated
- €1.2m▲ 4.3%
- ≈ 0 FTEestimated
- Filing
- Filed on 12-08-2026
Insights on JOLYPHARMA
JOLYPHARMA files the abbreviated format. That format states no turnover. The gross margin rose from €133,597 in 2006 to €169,801 in 2025.
The balance sheet grew most from 2015 to 2017 through fixed assets.
In December 2023, the Official Gazette published the appointment of as managing director.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about JOLYPHARMA
- What is the company number of JOLYPHARMA?
- The company number of JOLYPHARMA is 0473.899.537. The VAT number is the same number with BE in front: BE 0473.899.537.
- Where is JOLYPHARMA based?
- The registered office is at Maastrichtersteenweg 180, 3770 Riemst.Company details
- What does JOLYPHARMA do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of JOLYPHARMA?
- JOLYPHARMA is a public limited company (NV).
- When was JOLYPHARMA founded?
- JOLYPHARMA was founded on 24-01-2001.
- Is JOLYPHARMA still active?
- Yes, JOLYPHARMA is an active enterprise in the KBO register.
- How many employees does JOLYPHARMA have?
- JOLYPHARMA had an average of 0.5 full-time equivalents in financial year 2020, according to the filed annual accounts.Financials
- What is the turnover of JOLYPHARMA?
- The turnover in financial year 2025 is ≈ €800,000. This figure is estimated from the gross margin of €169,801 and 43 comparable companies (NACE 477). It probably lies between €520,000 and €1.7m.
- Is JOLYPHARMA profitable?
- In financial year 2025, JOLYPHARMA made a profit of €93,466.
- Where can I find the annual accounts of JOLYPHARMA?
- JOLYPHARMA filed 20 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of JOLYPHARMA due?
- JOLYPHARMA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.